Mylan NV develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company was founded in 1961 and is based in Potters Bar, Hertfordshire.
MYL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Mylan NV. To summarize, we found that Mylan NV ranked in the 68th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 208.5%. The most interesting components of our discounted cash flow analysis for Mylan NV ended up being:
39% of the company's capital comes from equity, which is greater than merely 19.33% of stocks in our cash flow based forecasting set.
Mylan NV's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 16.18% of tickers in our DCF set.
Relative to other stocks in its sector (Healthcare), Mylan NV has a reliance on debt greater than 87.75% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
SGRY, ALXN, LXRX, LCI, and HZNP can be thought of as valuation peers to MYL, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Mylan (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the companies have received final approval from the European Commission (EC) for the proposed combination of Mylan and Pfizer Inc.'s Upjohn…
FDA approves Blueprint’s GAVRETO for lung cancer Blueprint Medicines Corporation (BPMC) announced that the FDA has given its approval to GAVRETO for treating adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer. Blueprint is collaborating with Roche (RHHBY), and the drug will be commercialized in the United...
Avisol Capital Partners on Seeking Alpha | September 10, 2020
HERTFORDSHIRE, England and PITTSBURGH, Sept. 9, 2020 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury, together with President Rajiv Malik will present at the BofA Securities Virtual Global Healthcare Conference…
Mylan N.V. (MYL) and Biocon Biologics India, a subsidiary of Biocon Ltd. (BCNQY), announce the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not...